Due to COVID-19, the AAAAI Annual Meeting was canceled and the research released to the public. Research highlights included long-term studies from new biologics and important advances in asthma, atopic dermatitis, and immunology care.
MD /alert has compiled a list of the top five abstracts you can’t miss.
FeNO Predicts Exacerbations in Patients with Moderate-to-Severe Asthma
Fractional exhaled nitric oxide (FeNO) may be a reliable biomarker for predicting exacerbations in patients with moderate-to-severe asthma. READ MORE.
World Trade Center Rescue Workers Have Unique Small Airways Dysfunction Decades After Disaster
“Seventeen years after exposure to the WTC disaster, exposed patients experience small airways dysfunction characterized by increased distal airways resistance and reactance not explained by obesity, smoking history, or allergic disease,” Dennis L. Caruana, said in an interview. READ MORE.
Benralizumab Demonstrates Safety, Efficacy at 3 Years for Moderate-to-Severe Asthma
At 3 years, benralizumab continues to lower exacerbation rates and improve lung function in adults and adolescents with severe, uncontrolled asthma. READ MORE.
Clinicians May be Underdosing Epinephrine for Anaphylaxis with Current Autoinjectors
While international guidelines recommend a 0.5 mg dose of epinephrine in older adults and children, current autoinjectors use 0.3 mg doses of epinephrine, which can lead to “an effective underdosing of 30% by body weight,” in a person weighing 40 kg, Paul J. Turner, MD, PhD, said in an interview. READ MORE.
Clinical, Demographic Factors Predict Systemic Allergic Reaction to Peanut Oral Immunotherapy
Pediatric patients with peanut allergy who received the oral immunotherapy drug AR101) were more likely to have a systemic allergic reaction to the therapy if they had peanut-specific immunoglobulin E, a history of peanut-related anaphylaxis, or were of a certain age or ethnicity. READ MORE.